Clozapine alone versus clozapine and risperidone for refractory schizophrenia [1]

New England Journal of Medicine

Volumn 354, Issue 17, 2006, Pages 1846-

  Grass, Guido ^a   Hellmich, Martin ^a   Markus Leweke, F ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

DRUG EFFECT; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; DRUG COMBINATION; EPIDEMIOLOGY; NOTE; AGRANULOCYTOSIS; CHEMICALLY INDUCED DISORDER; LEUKOCYTE COUNT; CONFIDENCE INTERVAL;

ANTIPSYCHOTIC AGENTS; BIAS (EPIDEMIOLOGY); CLOZAPINE; DRUG THERAPY, COMBINATION; HUMANS; RISPERIDONE; SCHIZOPHRENIA; AGRANULOCYTOSIS; LEUKOCYTE COUNT; CONFIDENCE INTERVALS;

EID: 33646110489     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc060588     Document Type: Letter

References (4)

1. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-82.
2. Davis JM. The choice of drugs for schizophrenia. N Engl J Med 2006;354:518-20.
3. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005; 66:1122-9.
4. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005;20:409-15.